Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedMC
Mubadala Capital
Activity from announced rounds
Activity in this selectionUnited States · Jun 30, 2026 · Jun 1, 2026
Mubadala Capital is the investment manager whose official portfolio includes Ollin, Alloy, Juvena and Crusoe.
Recorded funding activity
Ollin develops retinal-disease antibodies. Alloy supplies discovery platforms and services, while Crusoe develops computing infrastructure. The manager remains separate from Mubadala Investment Company; the Precision Neuroscience relation stays in draft.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $330M 1 disclosed · full round size, not this investor’s share